Gastro Esophageal Junction Cancer Active Not Recruiting Phase 3 Trials for Fluorouracil (DB00544)

Back to Gastro Esophageal Junction Cancer

Also known as: Gastroesophageal-junction Cancer / Gastroesophageal Junction Cancer / Gastro-oesophageal Junction Cancer / Gastro-esophageal Junction Cancer / Gastrooesophageal junction cancer / Carcinoma of oesophagus NOS / Carcinoma of oesophagus / Carcinoma of esophagus (disorder) / Carcinoma of esophagus / Oesophageal carcinoma NOS / Oesophageal carcinoma / Esophageal carcinoma NOS / Esophageal carcinoma / Primary malignant neoplasm of esophagus (disorder)

Indication	Status	Phase
DBCOND0106887 (Gastro Esophageal Junction Cancer)	Active Not Recruiting	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02872116	Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Treatment	Capecitabine (DB01101) Fluorouracil (DB00544) Ipilimumab (DB06186) Leucovorin (DB00650) Nivolumab (DB09035) Oxaliplatin (DB00526)
NCT03221426	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)	Treatment	Capecitabine (DB01101) Cisplatin (DB00515) Docetaxel (DB01248) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526) Pembrolizumab (DB09037)